IGC Pharma预期从大麻重新分类为附表三中受益,从而推进其老年痴呆症的药物试验和研究。 IGC Pharma expects benefits from cannabis reclassification to Schedule III, advancing its Alzheimer’s drug trial and research.

IGC Pharma是一个临床生物技术阶段,为阿尔茨海默老年痴呆症开发由林业发展局管制的大麻素疗法,他说,它完全能够受益于联邦将大麻重新分类为附表三的势头,这可以减轻研究、制造和投资的监管障碍。 IGC Pharma, a clinical-stage biotech developing FDA-regulated cannabinoid therapies for Alzheimer’s, says it is well-positioned to benefit from federal momentum to reclassify cannabis to Schedule III, which could ease regulatory hurdles for research, manufacturing, and investment. 其主要候选人IGC-AD1正因阿尔茨海默氏病引起的骚动进行第二阶段试验。 Its lead candidate, IGC-AD1, is in a Phase 2 trial for Alzheimer’s-related agitation. 与以消费者为重点的大麻公司不同,IGC在药物开发途径内运作,强调低剂量、非精神活性、由AI驱动的配方,并辅之以临床鉴定。 Unlike consumer-focused cannabis firms, IGC operates within the pharmaceutical development pathway, emphasizing low-dose, non-psychoactive, AI-driven formulations backed by clinical validation. 该公司认为,更明确的联邦政策可以促进机构参与、供应链稳定性和资本参与,协调对大麻素药物的科学、监管和投资。 The company believes clearer federal policy could boost institutional participation, supply chain stability, and capital engagement, aligning science, regulation, and investment in cannabinoid medicines.